Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...

BERLIN -- Adding a test that predicts cancer signal origin to single standard of care (SoC) screening substantially increased ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...

“Our findings show that RNA-based testing can uncover hidden risks in multiple myeloma that DNA tests alone miss,” study ...

When Erica Barnell was an MD/PhD student at Washington University in St. Louis, she met a woman who had stage four colorectal cancer (CRC). The woman was only 52 years old—more than a decade younger ...

The discovery began, as many breakthroughs do, with an observation that didn’t quite make sense. In 1948, two French researchers, Paul Mandel and Pierre Métais, published a little-noticed paper in a ...

SAN DIEGO — In the ever-expanding options for colorectal cancer (CRC) screening, blood tests using precision medicine are becoming more advanced and convenient than ever; however, caveats abound, and ...

Ebihara Takashi has been the chief operating officer of GeneFrontier (GFC) since 2010, with a focus on advancing cell-free protein expression technologies, particularly the PURE system. He earned a ...

In recent years, the market size for cell-free DNA (cfDNA) kits has expanded swiftly. This market is projected to increase from $1.60 billion in 2024 to $1.80 billion in 2025, marking a compound ...